Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue Post published:February 1, 2023 Post category:Press Release
Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea Post published:February 1, 2023 Post category:Press Release
Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial Post published:February 1, 2023 Post category:Press Release
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound Post published:January 31, 2023 Post category:Press Release
Silo Pharma Announces Stock Repurchase Program Post published:January 31, 2023 Post category:Press Release
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency Post published:January 28, 2023 Post category:Press Release
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments Post published:January 27, 2023 Post category:Press Release
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023 Post published:January 25, 2023 Post category:Press Release
Small Pharma Reports Fiscal Third Quarter 2023 Highlights Post published:January 25, 2023 Post category:Press Release
Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023 Post published:January 25, 2023 Post category:Press Release